Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2019
Filed with the SEC on Mar 23, 2020 and accepted by EDGAR at Mar 23, 2020, 17:17 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | $1.0m | ifrs-full:Revenue |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$7.2m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $216.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$5.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $11.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2019-12-31 | $4.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2019-12-31 | $8.3m | ifrs-full:CurrentAssets |
| Total assets | At period end2019-12-31 | $14.7m | ifrs-full:Assets |
| Current liabilities | At period end2019-12-31 | $3.5m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2019-12-31 | $10.4m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2019-12-31 | 19,564,449 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-20-007156. Last ingested by Listed: Nov 6, 2026, 18:16 ET. Listed shows no prices and gives no investment advice.